CLAAS Celebrates Milestone with Special TERRA TRAC Combine

Dec 03, 2024
By Ryan Ridley
Assistant Editor, North American Content, Farms.com

Special Wrapped Combine for 500,000th Units Produced

In case you missed it, CLAAS has rolled out a special edition combine to celebrate a special milestone.

The company recently celebrated the production of 500,000 global combines.

CLAAS has unveiled its newest flagship combine harvester: the 8900 TERRA TRAC wrapped in a special edition design.

This machine is specifically designed for the North American market, boasting a maximum engine output of 780 horsepower, making it ideal for large-scale farms seeking to maximize productivity and efficiency.

Beyond its power, the 8900 TERRA TRAC incorporates several features designed to enhance performance and user experience. The machine prioritizes throughput, allowing you to harvest larger areas in less time.

Additionally, the new TERRA TRAC emphasizes efficiency, minimizing operational costs and maximizing output.

Farms.com caught up with Greg Frenzel to take a look at the new specially wrapped combine.

Watch the below video to see it for yourself.

Video: Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Regulations help markets and industry exist on level playing fields, keeping consumers safe and innovation from going too far. However, incredibly strict regulations can stunt innovation and cause entire industries to wither away. Dr. Peter James Facchini brings his perspective on how existing regulations have slowed the advancement of medical developments within Canada. Given the international concern of opium poppy’s illicit potential, Health Canada must abide by this global policy. But with modern technology pushing the development of many pharmaceuticals to being grown via fermentation, is it time to reconsider the rules?

Dr. Peter James Facchini leads research into the metabolic biochemistry in opium poppy at the University of Calgary. For more than 30 years, his work has contributed to the increased availability of benzylisoquinoline alkaloid biosynthetic genes to assist in the creation of morphine for pharmaceutical use. Dr. Facchini completed his B.Sc. and Ph.D. in Biological Sciences at the University of Toronto before completing Postdoctoral Fellowships in Biochemistry at the University of Kentucky in 1992 & Université de Montréal in 1995.